Cantor Fitzgerald Reiterates Overweight on Portage Biotech, Maintains $11 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Li Watsek has reiterated an Overweight rating on Portage Biotech (NASDAQ:PRTG) and maintained a price target of $11.
September 07, 2023 | 3:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst has reiterated an Overweight rating on Portage Biotech and maintained a price target of $11.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Portage Biotech. The maintained price target of $11 suggests that the analyst believes the stock is still undervalued, which could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100